Skip to content

Study on mechanism of acupoint catgut embedding to interfere with AI treatment related dyslipidemia of breast cancer based on ERa-LDLR pathway

Study on mechanism of acupoint catgut embedding to interfere with AI treatment related dyslipidemia of breast cancer based on ERa-LDLR pathway

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2024000499
Enrollment
Unknown
Registered
2024-09-28
Start date
2019-01-01
Completion date
Unknown
Last updated
2024-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer

Interventions

Control group:False point embedding
Experimental group:Point embedding

Sponsors

Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences)
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
28 Years to 67 Years

Inclusion criteria

Inclusion criteria: Patient case criteria were included (1) After surgical resection of primary breast cancer the case tissue test belongs to TNBC; (2) Within 6 months after TNBC there was no recurrence or metastasis in patients with improved relevant examinations; (3) Postoperative adjuvant therapy was performed according to the guidelines; (4) The patient was in good condition with KPS and Karnofsky scores ranging from 60 to 100 as shown in Table 3; (5) Female patients aged 18-70 years; (6) no serious liver and kidney function abnormalities or other organic and functional diseases; (7) Sign informed consent communicate without barriers and be willing to accept treatment observation and various examinations.

Exclusion criteria

Exclusion criteria: Exclusion criteria (1) Those who do not meet the above inclusion criteria; (2) Patients with elevated tumor markers imaging evidence of mass or palpation of unknown causes; (3) Patients who do not accept traditional Chinese medicine treatment and do not accept acupuncture point embedding; (4) For patients with embedded or xenoprotein allergy (5) Zusanli skin diseases and mental patients; (6) Subjects who are taking other treatments or drugs;

Design outcomes

Primary

MeasureTime frame
Tumor recurrence rate;

Secondary

MeasureTime frame
Karnofsky score;CA125;TNF-a;VEGF;VAS-F score;

Countries

China

Contacts

Public ContactXiaohe Lan

Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences)

942635415@qq.com15013080403

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026